SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Parmax Pharma gets nod for plant expansion for manufacturing of API products

20 Jun 2018 Evaluate

Parmax Pharma has received an approval for expansion of plant for manufacturing of API products under Goods Manufacturing Practices. The Board of Directors at their meeting held on June 17, 2018, approved the same.

Parmax Pharma deals in all kinds of drug and drugs used in pharmaceutical, medicinal biological immunological, contraceptive and therapeutim preparations, substance materials and articles of all classes and description.

Parmax Pharma Share Price

69.38 1.36 (2.00%)
19-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1837.15
Dr. Reddys Lab 1271.55
Cipla 1353.85
Zydus Lifesciences 1070.90
Lupin 2351.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: